Pane wikiwiki
Effectively translate machine learning-generated peptide prediction data into practical, lab-grade synthetic sequences. Master core technical workflows including manufacturability screening filters, standardized Fmoc solid-phase peptide synthesis (SPSS) chemistry protocols, and systematic experimental validation milestones to ensure predicted peptide sequences are feasible, hale paʻa, and fully producible in laboratory and industrial settings.
Hoʻopili i nā wānana ML Peptide i nā kaʻina hoʻomākaukau Lab: Nā haʻawina mai nā hiʻohiʻona nui a me nā haʻawina hoʻolālā

Naʻauao hana hoʻomohala, nā algorithms diffusion, a ua hoʻololi nā hiʻohiʻona ʻōlelo nui i ke ala o ka ʻike ʻana i ka peptide. Hiki i nā papa helu helu ke loiloi i nā piliona o nā kaʻina moho i nā hola, ka helu ʻana i nā moho no ka pilina pili, ke koho koho, a wānana ʻia ke kūkulu lua. Eia naʻe, ʻIke pinepine nā hui noiʻi i kahi hāʻule nui o nā helu kūleʻa i ka wā e hoʻololi ai mai ka silico hits i ka hoʻāʻo ʻana i ka wai-lab kino.. ʻO kahi peptide i hoʻopaʻa ʻia e helu ʻia ma luna 0.1% hiki ke hāʻule loa i ka wā paʻa-phase peptide synthesis (SPSS), hōʻuluʻulu i ka wā o ka wehe ʻana o TFA, a i ʻole e hana i nā hui colloidal e hoʻopuka ana i nā hōʻailona maikaʻi ʻole i ka hoʻāʻo ʻana.
Ka unuhi ʻana i nā wānana aʻo mīkini i loko o ka hoʻāʻo, ʻO nā peptides maʻemaʻe kiʻekiʻe e koi i kahi hoʻokolohua hoʻokolohua hoʻāʻo ʻana. Ma mua o ka mālama ʻana i nā hoʻopuka helu helu ma ke ʻano he moho hope, Hoʻohana nā hui alakaʻi i kahi kānana hana lua e loiloi i nā palena hui kino, hoʻolauna i nā kemika hoʻololi wānana, a hoʻokomo i nā moho i kahi paipu hōʻoia orthogonal 4-tier ma mua o ka hoʻokomo ʻana i nā bioassays nui..
No ke aha e hana ai nā kumu hoʻohālike o ka mīkini aʻo i nā hemahema Wet-Lab
ʻO ka hapa nui o nā hiʻohiʻona hoʻonaʻauao hohonu no ka hoʻolālā peptide e hana i kahi ikehu kūpono a i ʻole ke kahua kūkulu. Hoʻomaʻamaʻa ʻia nā algorithm ma nā ʻōnaehana co-crystal PDB static a i ʻole ka ʻikepili pili i hoʻopaʻa ʻia no ka ikehu pilina pili., electrostatic complementarity, a me ka paʻa dihedral iwi kuamoʻo. Eia naʻe, ʻAʻole hiki i kēia mau hiʻohiʻona ke hoʻokomo i ka physics kemika o ka elongation kaulahao peptide stepwise ma ke kākoʻo paʻa..
I ka wā e hoʻohua ai ke kumu hoʻohālike helu i kahi kaʻina 20-mer a i ʻole 30-mer i waiwai i nā koena hydrophobic, Nā kumu hoʻolaha β-pepa, a i ʻole nā kaulahao ʻaoʻao nui, ke nānā aku nei i nā mīkini kino o ka hui peptide. I ka wā o Fmoc solid-phase peptide synthesis, i ka hiki ʻana o ke kaulahao peptide ulu 8 i 15 nā amino acids i ka lōʻihi, Hiki i ka hoʻopaʻa ʻana o ka hydrogen inter-chain a me ka intra-chain ke hoʻoulu i ka hoʻokumu ʻana i ka hoʻokumu ʻana o ka papa kiʻekiʻe β-sheet ma luna o ka matrix resin.. ʻO kēia hanana, ʻike ʻia ʻo ka resin aggregation, kaohi ʻana i ka pehu ʻana o ka mea hoʻoheheʻe a pale i ka amine N-terminal mai nā waikawa amino e komo mai ana..
Ki Takeaway: ʻAʻole hōʻoia nā helu hoʻopaʻa helu kiʻekiʻe i ka synthesizable kino. Hoʻopili pinepine nā huahana aʻo mīkini i kānana ʻole ʻia i nā koena hydrophobic a me ka β-sheet-promoting koena e hoʻoulu ai i ka hui resin koʻikoʻi., hoʻopili piha ʻole, a me nā mea haumia i ʻoki ʻia i ka wā o ka synthesis paʻa.
ʻO ka hui ʻana o Resin e alakaʻi i ʻelua mau ʻano hemahema mua i ka hoʻokō wet-lab:
- Hoʻopau Fmoc Deprotection: Hoʻopaʻa ʻia ka hui ʻana ma waena o ka piperidine i ka hui N-terminal Fmoc. I ke kahe ana, hōʻike ʻia kēia ma ke ʻano he palahalaha a hoʻonui ʻia i nā profile deprotection UV. I ka hui pū ʻana, ʻoki ʻia nā lau deprotection ʻole, Mālama ʻia ʻo Fmoc, a i ʻole nā huahana ʻaoʻao acetylated i paʻakikī ke hoʻokaʻawale ʻia mai ka peptide i hoʻopaʻa ʻia e ka hoʻomākaukau hoʻohuli ʻana i ka HPLC..
- ʻO ka hoʻohui ʻana i ka hoʻokuʻu ʻana a me ka Steric Hindrance: Nā koena pili puʻupuʻu nui a paʻa paha (e like me ka consecutive Arg, Me, ʻO Val, a i ʻole nā hui Leu) hana i ka hoʻopaʻapaʻa steric kūloko. Nā ho'āʻo hoʻohui kalaimetric maʻamau, me ninhydrin a me TNBS, hāʻawi pinepine i nā hopena hoʻopunipuni i ka wā e hāʻule ai ka resin koʻikoʻi, e hūnā ana i nā kaulahao i hana ʻole ʻia a hiki i ka hōʻike ʻana o ka spectrometry nui i nā kaʻina holoi holoi.
Nā kānana no ka hana ʻana i ke kaʻina hana nui
No ka pale ʻana i nā kaʻina make-end mai ke komo ʻana i ka pipeline synthesis, Pono ka helu helu helu ma nā kānana triage quantitative ma mua o ka hoʻomaka ʻana o ka synthesis.
Hanau Moho (Ma Silika) → Hiki ke hana & ʻO ka nānā ʻana i ka hui ʻana → Hoʻololi Kemika & Hoʻolālā Palekana → Hui SPPS Kino → QC Biophysical Tiered
1. Hoʻopale ʻia i loko o ka laina Fmoc & Nā Ana Hoʻohui Hoʻonā
Hoʻohui ka nānā ʻana i ka Synthesizability i nā meheu kahe o ka mōʻaukala me nā lula kemika kino. Hoʻohālikelike ʻia nā anana koʻikoʻi ʻelua:
- Kumu Houluulu (NO): Loaʻa mai ka hoʻoheheʻe ʻana o UV i ka wā o ka wehe ʻana o Fmoc i ka synthesis kahe, wehewehe ʻia ʻo ia ka ʻokoʻa ma waena o ka laula peak deprotection a me kona kiʻekiʻe (AF = Wₙ – Hₙ). Nā kaʻina e hōʻike ana i kahi AF > 20 a i ʻole ka hoʻonui ʻana o ka piko deprotection ma mua o 20% pili i nā pōʻai mua e lawe i ka pilikia synthesis koʻikoʻi. E like me ka hōʻike ʻana ma ke aʻo ʻana ʻo Nature Chemistry ma ka peptide synthesis aggregation (2026), ʻO ka haku mele a me ka hui ʻana o ka hydrophobic e alakaʻi i kēia mau anomalies deprotection.
- Papa kuhikuhi houluulu (AI): Loiloi i ka hui colloidal solution-state me ka hoʻohana ʻana i ka spectrophotometry UV ma waena o ʻelua mau nalu: AI = (A₃₅₀/A₂₈₀ – A₃₅₀) × 100 ʻO kahi AI ma lalo 3 hōʻike i kahi maopopo, monomeric solution. He AI ma waena 3 a 30 hōʻike i ka oligomerization māmā, ʻoiai he AI ma luna 30 hōʻike i ka hōʻuluʻulu colloidal koʻikoʻi e hoʻopilikia i ka chromatography wai a me nā hoʻokolohua biological.
2. Hydropathicity, Hoʻopiʻi, a me ka manaʻo hoʻolālā
Hoʻoholo ka haku mele ʻana i ka pono SPPS a me ka hoʻoheheʻe wai:
- KAHUA (Awelika Nui o ka Hydropathicity): Nā kaʻina me ka helu GRAVY ʻoi aku ka nui ma mua o +0.4 He hydrophobic nui a hiki i ka ua i ka wā hoʻomaʻemaʻe HPLC.
- Nā Triad Hydrophobic: Nā ʻakika amino hydrophobic (e.g., Koho-Koho-Koho, Phe-Ile-Leu, Trp-Trp-Val) e hoʻoulu i ka hōʻuluʻulu β-sheet wikiwiki i ka wā SPPS. Ke hoʻokomo nei i nā koena i kau ʻia (Lys, ʻO Arg, ʻO Glu) a i ʻole nā ʻakika amino hoʻohaunaele i ka hale e hōʻemi i kēia ʻano.
- Lae Isoelectric (pI) Hoʻopololei: ʻO nā peptides me kahi pI kokoke i ka pH buffer physiological (pH 7.0–7.4) hōʻike pinepine ʻole i ka solubility i ka wā o ka hoʻāʻo ʻana ma ke kelepona.
3. Nā Manaʻo Kūleʻa Kemika a me nā ʻaoʻao
Pono e hoʻopaʻa ʻia nā hoʻolālā hoʻolālā no nā hui waika amino reactive e hoʻohaʻahaʻa ʻia i ka wā synthesis., māwae, a i ʻole ka waiho ʻana:
- ʻO Asp-Pro Cleavage: ʻO nā paʻa dipeptide acid-labile e hana i ka autolysis wikiwiki i ka wā maʻamau 95% Māhele TFA.
- Hoʻokumu ʻia ʻo Asn-Gly a me Asp-Gly Aspartimide: ʻO ka pani ʻana o ke apo ma lalo o nā kūlana deprotection piperidine maʻamau e loaʻa i nā mea waena succinimide, ka hopena i ka α- a me nā huahana ʻaoʻao β-aspartyl.
- Met a me Trp Oxidation: ʻO nā koena methionine hiki ke hoʻokahe ʻia i sulfoxides, ʻoiai ʻo tryptophan e hana i nā huahana t-butylated a i ʻole polymeric ʻaoʻao i ka wā o ka TFA cleavage inā scavenger cocktails (e.g., EDT, thioanisole, wai, phenol) ua kaulike hewa.
- N-Terminal Gln Cyclization: ʻO Glutamine ma ke kūlana 1 hoʻomaka koke i ka pyroglutamate ma lalo o nā kūlana mālama ʻawaʻawa a kū ʻole paha.
ʻO ka nui o ka hana Triage Matrix
| Metric / Hiʻona | Palena Kūlana kūpono | palena palena (Pono i nā mea kōkua kemika) | Paepae hōʻole pilikia kiʻekiʻe | Wet-Lab Ka hopena |
|---|---|---|---|---|
| Ka lōʻihi (Koena) | 5 – 25 nā ʻakika amino | 26 – 40 nā ʻakika amino | > 45 nā ʻakika amino | ʻO ka hāʻule nui ʻana o ka hua kō; kiʻekiʻe truncation rate |
| Helu GRAVY | -0.8 i +0.2 | +0.2 i +0.5 | > +0.5 | ʻAʻole hiki ke hoʻoheheʻe ʻia i ka wai; hoʻomaʻemaʻe hemahema |
| Kumu Houluulu (NO) | < 10 | 10 – 20 | > 20 | Nā kiʻekiʻe deprotection Fmoc palahalaha; nā ʻakika amino ʻole |
| Lae Isoelectric (pI) | < 5.5 a i ʻole > 8.5 | 5.8 – 6.5 a i ʻole 7.8 – 8.2 | 6.8 – 7.5 | Isoelectric precipitation i loko o ka physiological buffers |
| Maʻiʻo Cys | 0 – 2 koena | 3 – 4 koena (hoomaluia) | > 4 ʻO Cys i hoʻopaʻa ʻole ʻia Hoʻohuihui Peptide | Ua hewa nā alahaka disulfide; oligomerization oxidative |
| Met pale ʻole / Trp | 0 koena | 1 koena (koi ʻia ka scavenger) | ≥ 2 koena | ʻO ka oxidation wikiwiki a me ka hoʻohui ʻana i ka wā o ka cleavage TFA |
Ma ka wānana Silico vs. ʻOiaʻiʻo ʻo Wet-Lab kino
<tIn Ka Ho'opono 'Ono Silico Mea hoʻolako Code Peptides“>Domain hiʻona
I ka Silicon Optimization Focus
Kaohi-Lab kino kino / ʻAno hāʻule
Hoʻolālā Hoʻomaʻamaʻa Hoʻomaʻamaʻa
<E hoʻohana i nā resins PEG hoʻololi haʻahaʻa a me nā mea hoʻohui chaotropic (LiCl/DMF) Ch Peptide(ʻO Arg, Me, ʻO Val)
| Hoʻolālā ʻelua | Hoʻonui i ka α-helix / β-pepa paʻa ma ka pae hoʻopaʻa paʻa | ʻO ka hui pū ʻana o ka β-sheet ma waena o ke kākoʻo resin | E hoʻokomo i nā pseudoproline dipeptides a i ʻole nā hui pale kuamoʻo (Dmb/Hmb) |
| Koena Hydrophobicity | Hoʻopili i nā core hydrophobic no ka pilina paʻa kiʻekiʻe | Haʻahaʻa hoʻoheheʻe wai, HPLC ua, a me ke kolamu hewa | Puunaue uku kaulike; hoʻokomo i nā hōʻailona polar solubilizing |
| Hoʻoloʻa kaulahao | Manaʻo i ka hoʻohui ʻana i ke kaʻina laina me ka ʻole o ka pale steric | E hoʻohana i nā resins PEG hoʻololi haʻahaʻa a me nā mea hoʻohui chaotropic (LiCl/DMF) | |
| Mea Kūʻai Peptide Hoʻohui Pahuhi | Nā helu ΔG a me nā kinetics paʻa i ke kūlana monomeric maikaʻi | ʻAʻohe-specific colloidal self-assembly kumu hoʻopaʻa promiscuous | E hōʻoia i ka monodispersity mokuʻāina hoʻonā ma o DLS (PdI <0.15) & SEC-MALS |
Nā Kemika Hoʻololi Manaʻo a me nā Kokua Synthetic
Ke hōʻike ʻia kahi kaʻina hoʻohiki hoʻohālikelike i ka hana palena palena, ʻAʻole pono ka poʻe noiʻi e hoʻolei loa i ka pā. Hāʻawi ka biology kemika i nā hana hoʻolālā e hoʻopau koke i ka hale kiʻekiʻe i ka wā SPPS a i ʻole e hoʻopaʻa i ke kaʻina no ka lawelawe lab..
1. ʻO Pseudoproline Dipeptides a me nā Pūʻulu Hoʻomalu Iwi
No ka pale ʻana i ka hui ʻana o ka resin i ka wā e hoʻolōʻihi ʻia ai ke kaulahao, Ua hoʻi au e hoʻolauna i nā chemists synthesis
Pseudoproline Dipeptides: Hoʻohui ʻia nā derivatives oxazolidine o Serine a i ʻole Threonine—e like me Fmoc-Xaa-Thr(Ψᵐᵉ˒ᵐᵉpro)-OH or Fmoc-Xaa-Ser(Ψᵐᵉ˒ᵐᵉpro)-OH—hoʻokomo i ka cis-conformation ma ka palapala peptide. Hana kēia kink ma ke ʻano he β-sheet breaker i ka wā SPPS, mālama i ka pehu resin. Ma ka ʻoki hope ʻana o TFA, ke apo oxazolidine wehe quantitative e huahua maoli Ser a Thr. Peptide
n ka mahele hope o TFA, ke apo oxazolidine wehe quantitative e huahua maoli Ser a Thr.
- N-Dmb a me N-Hmb i ka iwi kuamoʻo: ʻO nā mea hoʻopuka e like me N-(2,4-dimethoxybenzyl) (Dmb) a i ʻole N-(2-hydroxy-4-methoxybenzyl) (Hmb) hoʻololi i nā protons amide ma ka iwi kuamoʻo, ka hoʻopau ʻana i ka pūnaewele hoʻopaʻa hydrogen inter-chain e hoʻokau i ka hoʻohui.
No ke kōkua: Ke synthesizing nā hoʻolālā helu ʻoi aku ka lōʻihi ma mua o 20 koena i loaʻa nā kāhuna hydrophobic, e hoʻolālā mua i ka hoʻokomo ʻana i nā pseudoproline dipeptides ma nā kūlana Xaa-Ser a i ʻole Xaa-Thr.. Hiki i kēia hoʻololi hoʻokahi ke hoʻololi i kahi kaʻina uncouplable loa i kahi synthesis kiʻekiʻe.
</co
Ghp Peptide Company Pseudoproline Intervention
rowspan=”1″>
'ikamu
| kikoʻī | |
|---|---|
| Ke Kaʻina Hui ʻŌiwi | H-Leu-Val-Val-Ile-Thr-Leu-Val-Gly-OH (Hoʻohui Resin kiʻekiʻe) |
| Pseudoproline Intervention | H-Leu-Val-Val-Ile-[ʻO Thr(Ψᵐᵉ˒ᵐᵉpro)]-Leu-Val-Gly-OH (Hoʻopili ʻia ka β-Sheet Structure) |
| Mahope o ka TFA Cleavage Huahana | H-Leu-Val-Val-Ile-Thr-Leu-Val-Gly-OH (Kaʻina Pahuhopu ʻōiwi) |
2. ʻO ka Resin Architecture a me ka Solvent System Optimization
ʻO ka hoʻohālikelike ʻana i ke kākoʻo kino i nā hiʻohiʻona ʻano mea nui no nā peptides paʻakikī:
- Palena PEG pani haʻahaʻa: ʻO nā resins polystyrene kuʻuna me ka hoʻololi kiʻekiʻe (0.6–1.0 mmol/g) e hoʻoulu i ka hoʻopaʻapaʻa steric wikiwiki no nā peptides lōʻihi a i ʻole i kūkulu ʻia. Ke hoʻololi nei i nā kākoʻo kumu polyethylene glycol (e.g., TentaGel, NovaPEG, PEGA) me na uku pani haahaa (0.15–0.25 mmol/g) hoʻonui i ka nui o ka pehu resin a mālama i ke komo ʻana i nā wahi hoʻohui.
- Nā mea hoʻohui Chaotropic a me nā mea hoʻoheheʻe i hui ʻia: Hoʻohui i nā paʻakai chaotropic e like me LiCl (0.8 M ma DMF) a i ʻole e hoʻololi i ka DMF maʻamau me NMP, DMA, a i ʻole nā hui binary i loaʻa i ka DMSO e hoʻopau i nā hōʻuluʻulu non-covalent i ka wā o ka hoʻopili paʻakikī..
3. Bio-Orthogonal Conjugation a me Cyclization
Pono nā hoʻololi e hilinaʻi i ka wānana, kiʻekiʻe-hua chemistries e pale aku non-specific aoao reactions:
- Kaomi i ke Kemika (SPAAC & CuAAC): No ka hōʻailona kikoʻī pūnaewele, ka hoʻohui ʻana i nā ʻakika amino non-canonical e lawe ana i ka azide (e.g., L-azidomoalanine) a i ʻole nā lima alkyne hiki i ke keleawe-free strain-promote azide-alkyne cycloaddition (SPAAC) me nā fluorophores hana DBCO, biotin, a i ʻole nā kaulahao PEG ma lalo o nā kūlana wai mālie.
- Stapling a me Cyclization: No ka laka ʻana i nā conformations α-helical i wānana ʻia, ka hoʻopaʻa ʻana o ka hydrocarbon ma o ka metathesis pani pani (RCM) a i ʻole lactam bridge cyclization ma waena o Lys a me Asp/Glu koena e hoʻonui ai i ka paʻa proteolytic a me ka permeability cell i ka wā e hoʻoponopono ai i ka conformation bioactive.
Nā Milestone hōʻoia ʻo Orthogonal
ʻO kahi pitfall nui i ka ʻike ʻana i ka peptide computational ka neʻe ʻana i nā hits synthetic crude pololei i ka hoʻopaʻa kiʻekiʻe-throughput a i ʻole nā mea hoʻāʻo e pili ana i ke kelepona.. Nā hōʻailona maʻemaʻe maikaʻiʻole, trace trace products, TFA koena, a me nā hui colloidal e hoʻopuka pinepine i nā hana hoʻopunipuni.
No ka hōʻoia ʻana i lilo i mea hilinaʻi ma silico hits, nā alakaʻi ʻepekema hiki ke hoʻāʻo, Pono nā polokalamu ʻike e hoʻokō i kahi palapala alanui hōʻoia orthogonal 4-tier.
Milestone 1: Paipa paʻa & Maemae (HR-ESI-MS / RP-HPLC ≥95%)
Milestone 2: Monodispersity & Mokuʻāina hoʻonā (DLS PdI <0.15 / SEC-MALS) Milestone 3: ʻO ka hoʻomaʻemaʻe hoʻomaʻemaʻe kiʻekiʻe (CD mamao-UV 190–250 nm) Milestone 4: Hoʻopaʻa Kinetic Direct (SPR / E LILO I NA NANA ANA I KA WA OLA)
Milestone 1: Hōʻoia intact mass a me ka maʻemaʻe (LC-MS)
- Pahuhopu Analitiki: E hōʻoia i ka hoʻohālikelike ʻana o ka mea kino i ka haku atomika pololei o ke kaʻina i hoʻolālā ʻia a kū i nā paepae maʻemaʻe liʻiliʻi..
- Kaʻina hana: ESI-TOF a i ʻole Orbitrap liquid chromatography-mass spectrometry (LC-MS) ke hana nei ma ke ʻano ion maikaʻi, hui pū me Ultra-Performance RP-HPLC me ka hoʻohana ʻana i kahi kolamu C18 a me kahi 0.1% TFA wai/acetonitrile gradient.
- Koina ʻae: Kuhi hewa nuipaʻa pololei ≤ 5 ppm; maʻemaʻe chromatographic ≥ 95% e ka hoʻohui pū ʻana o ka wahi kiʻekiʻe o UV ma 214 nm a 280 nm; ka pau ʻole o nā kaʻina holoi holoi ʻia a i ʻole nā hui pale i wehe ʻole ʻia. E like me ka mea kiko'ī ma ka PMC biophysical early drug discovery protocol (2020), ʻO ka hōʻoia nui nui ka puka komo hiki ʻole ke kūkākūkā no nā loiloi biophysical lalo..
Milestone 2: ʻO ka hoʻonā ʻana a me ka Monodispersity (DLS & SEC-MALS)
- Pahuhopu Analitiki: E hōʻoia i ka noho monodisperse ka peptide i loko o ka physiological buffer a ʻaʻole i hoʻokumu i nā hui colloidal non-specific e hoʻokau i ka hoʻopaʻa ʻana a i ʻole ka hoʻopaʻa wahaheʻe..
- Kaʻina hana: Hoʻopuʻi ʻana i ka māmā (DLS) ana i ka radius hydrodynamic (Rₕ) ma kahi o ka gradient concentrate (10 µM i 1 mM), kākoʻo ʻia e Size Exclusion Chromatography i hui pū ʻia me Multi-Angle Light Scattering (SEC-MALS).
- Koina ʻae: Ka helu helu polydispersity (PdI) < 0.15; hoʻokahi kiʻekiʻe symmetric ma SEC-MALS pili i ka monomeric i helu ʻia (a i ʻole dimeric i manaʻo ʻia) kaumaha molekala; ʻaʻole i pau ka ulu ʻana o nā ʻāpana pili i ka manawa 24 hola ma 25°C.
ʻŌlelo aʻo: Mai hoʻokuʻu i ka DLS a i ʻole SEC-MALS ma mua o ka hoʻopaʻa ʻana i ka ʻike a i ʻole ka ʻili. Hiki i nā sub-micron colloidal aggregates ke hoʻopili pono ʻole i nā paia microplate a i ʻole nā ʻāpana sensor., ka hana ʻana i nā hōʻailona pili ʻana i nā nanomolar e nalowale ana ke hoʻāʻo ʻia i nā mana monodisperse.
Milestone 3: ʻO ke kūkulu lua a me ka hoʻomaʻemaʻe pelu (CD Spectroscopy)
- Pahuhopu Analitiki: E hoʻoholo inā hoʻohana ka peptide synthesized i ka hana lua i wānana ʻia e AlphaFold, Rosetta, a i ʻole nā hiʻohiʻona generative.
- Kaʻina hana: Far-UV Circle Dichroism (CD) spectroscopy i hoʻopaʻa ʻia mai 190 nm i 250 nm i loko o nā cuvettes quartz (1 mm ka lōʻihi o ke alahele) ma lalo o nā kūlana pale like ʻole, nā mahana wela, a me nā wahi hoʻohālike membrane (e.g., TFE a i ʻole SDS micelles).
- Koina ʻae: Nā pūlima spectral ʻokoʻa e pili ana i nā ʻāpana wānana:
- α-Helix: ʻElua minima ma 208 nm a 222 nm, me ka piko maikai kokoke 190 nm.
- β-Pepa: Hoʻokahi maikaʻi ʻole ka palena iki ma 218 nm a me kahi piko maikaʻi kokoke 195 nm.
- ʻAi ʻAi Moku: Negative ka palena iki kokoke 198 nm (e hōʻike ana i ka hoʻohālikelike ʻole ʻia i ka hoʻonā).
Milestone 4: Hoʻopaʻa Kinetic Kūleʻa a me ka Hana Hana (SPR / LILO)
- Pahuhopu Analitiki: E helu i nā kinetics paʻa manawa maoli (helu hui kₒₙ, helu hoʻokaʻawale kₒff, a me ka hoʻokaʻawale kaulike K D) kū'ē i ka protein target.
- Kaʻina hana: ʻO ke kani ʻana o Plasmon Surface (SPR) a i ʻole Bio-Layer Interferometry (LILO). Hoʻokuʻu ʻia nā protein target ma o ka hui ʻana o ka amine a i ʻole biotinylation kikoʻī pūnaewele ma luna o nā ʻāpana sensor.. Hoʻokomo ʻia nā peptide i loko o kahi pūʻulu hoʻopaʻa ʻana he 0.1 × K D a hiki i 10 × K D..
- Koina ʻae: Pili-pili, saturable sensorgrams kūpono a 1:1 Hoʻohālike paʻa ʻo Langmuir; ka unuhi ʻana i ke alahele kuhikuhi ʻelua e hōʻoia ana i ka paʻa ʻole kikoʻī ʻole i ka matrix; ʻaelike ma waena o ke kinetic K D (kₒff / kₒₙ) a me ka helu ʻana i ka pilina paʻa.
Pākuʻi no ka Synthesis paʻakikī a me ka hoʻonui ʻana i ke kaʻina hana
ʻO ka unuhi ʻana i nā wānana aʻo mīkini i loko o nā kaʻina mākaukau lab e pono ai ka hoʻonohonoho paʻa ʻana ma waena o ka biology computational a me ka ʻike loea peptide chemistry.. Ke hoʻopau ʻia ka mana o loko o ka wet-lab a i ʻole nā mea hana synthesis i ka lawelawe ʻana i nā kaʻina paʻakikī, ʻO ka hui pū ʻana me kahi kahua noiʻi synthesis i hoʻolaʻa ʻia e hoʻopaʻa i ka hakahaka hoʻokō.
Ma ka MOL Changes, loea mākou i ka hoʻopili ʻana i ka mahele computational-to-lab no ka biotech kiʻekiʻe, lāʻau lapaʻau, a me nā hui noiʻi hoʻonaʻauao:
- Hoʻokaʻina Kūʻai Kūʻai Kūʻai & SPSS: Hoʻokō akamai i ka paʻakikī, hydrophobic, a i ʻole nā kaʻina hoʻohuihui me ka hoʻohana ʻana i nā ʻenehana hana paʻa paʻa a me ka kahe ʻana i hoʻohālikelike ʻia i nā hoʻolālā paʻakikī.. I nā hoʻokolohua benchmark me ka kiʻekiʻe-GRAVY (>+0.4) nā hoʻolālā helu, ʻO kā mākou hoʻolālā pseudoproline dipeptide proactive i hoʻomaikaʻi i ka awelika crude synthesis hua mai <15% e oi aku 82%.
- Papa 100 ʻO ka hoʻoponopono ʻana i ka lumi hoʻomaʻemaʻe Ultra-Sterile: No ka cell-based, organoida, a i ʻole nā noi vivo, Hoʻopili ʻia nā peptides a hana ʻia i loko o ka Papa 100 kaiapuni sterile, hāʻawi i nā mana sterility koʻikoʻi a hōʻoia i ka hana haʻahaʻa endotoxin (< 0.01 EU/mg).
- Kālā Hoʻololi Nui: Loaʻa i luna 300 nā hoʻololi hana, me nā ʻakika amino non-canonical, pseudoproline dipeptides, paena-specific kaomi lima, nā lepili fluorescent, a me ka hōʻailona isotope paʻa.
- Hooia-Makaukau Analytical QC: Loaʻa i kēlā me kēia peptide i hāʻawi ʻia, palapala kikoʻī pūʻulu—e hōʻike ana nā chromatograms HPLC kiko'ī a me nā kiko kikoʻī e hōʻoiaʻiʻo i ka ʻike, maʻemaʻe kiʻekiʻe (≥95%), a hoʻopiha piha i ka hailona-a-lot.
He papa inoa no ka unuhi ʻana ma ka Silico Peptide
E hoʻohālikelike i ka hoʻololi ʻana o nā wānana aʻo mīkini i loko o nā waiwai keʻena hoʻokolohua, e hoʻohana i ka papa inoa hana ma lalo nei:
- Hōʻoia i ke kaʻina hana mua
- E helu i ka helu GRAVY, kiko isoelectric, a me ke kumu houluulu (NO).
- Hae Asp-Pro, Asn-Gly, a me nā kumu Met/Trp i pale ʻole ʻia no ka hoʻohaʻahaʻa kemika.
- E hōʻoia i ka lōʻihi holoʻokoʻa a me ka uku ʻupena ma lalo o nā kūlana pH assay.
- ʻO ke koho hoʻolālā Synthetic
- E koho i nā resins PEG pani haʻahaʻa (0.15–0.25 mmol/g) no nā kaʻina > 20 koena.
- Hoʻokomo mua i nā pseudoproline dipeptides ma nā pūnaewele Xaa-Ser/Thr maoli i loko o nā wahi hydrophobic.
- E hoʻolālā i ka cocktails scavenger no nā kaʻina i loaʻa nā koena oxidation-sensitive.
- Hōʻoia ʻia ʻo Tiered Laboratory
- E hōʻoia i ka nuipaʻa paʻa e ka ESI-MS hoʻonā kiʻekiʻe (hewa ≤ 5 ppm) a me ka maemae (≥ 95% na HPLC).
- E loiloi i ka monodispersity e DLS (PdI < 0.15) ma mua o ka hoʻomaka ʻana i nā haʻawina paʻa.
- E hōʻoia i ka paʻi wānana e ka Far-UV CD spectroscopy.
- Hana i ka hoʻopaʻa kinetic SPR/BLI me ka unuhi ʻana i nā kaha ʻelua.
